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17(IQR 10-22).Smoking (54%) and diabetes (20%) were the most common cardiac
risk factors.Access route of choice was femoral (94%). Medtronic Corevalve was used
most commonly (68%).Permanent pacing was required in 18% of patients & 9% had
at least one major complication.Event free survival was signiﬁcantly higher (92% vs.
65%) in the later time periods (GP 2 and 3: n¼128) compared to that in the “learning
curve” group (GP1: n¼60), (log rank p¼0.003),(graph 1).There was a 50% reduction
in index procedure hospital stay for the latest cohort compared to the ﬁrst two
cohorts (GP1 & 2 median ¼ 8 days, IQR 4-16 days),(GP3:median:4 days,IQR
3-9 days),(p¼0.002).
Conclusions: One year all-cause mortality has improved and hospital stay has reduced
over three consecutive time periods.The mortality reduction does not relate to patient
characteristics and may have been driven by acquired skills and experience of the
TAVI team and advances in valve designs
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Background: Transcatheter aortic valve implantation (TAVI) has become the stan-
dard intervention for elderly patients with aortic stenosis. Implantation of the valve
without pre-dilatation might have some advantages by reducing procedural steps and
thereby also the complication rate. This has been demonstrated for the antegrade
transapical access with the ballon-expandable Edwards SAPIEN XT valve. However,
the feasibility of TAVI with a balloon expandable device without predilatation using
the retrograde transfemoral route has not been evaluated yet.
Methods: Twenty six consecutive patients with stenosis of the native aortic valve
undergoing transfemoral TAVI with the Edwards Sapien XT prosthesis were enrolled
in this study.
Results: The procedure was successfully performed in all 26 patients - irrespective of
the aortic valve area and the extent of aortic valve calciﬁcation. At baseline mean
aortic valve area, mean AV gradient and median LVEF were 0.7  0.2 cm2, 36.0 
17.3 mmHg and 55.0% [IQR 35.0 – 60.0]; prior to discharge these values changed as
follows: 1.7  0.3 (p < 0.001), 9.8  6.1 mmHg (p < 0.001) and 57.5% [IQR 38.7 –
60.0] (p ¼ ns). Postdilatation due aortic regurgitation > 2 was required in 3 cases,
leading to aortic regurgitation < 2 in all patients. Of note, no periprocedural
neurological adverse events occurred.
Conclusions: Transfemoral aortic valve implantation without pre-dilatation using the
Edwards Sapien XT is feasible and safe.
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Background: The Vancouver Program initiated multidisciplinary and multimodality
risk stratiﬁcation to determine patients’ suitability for a transfemoral (TF) minimalist
peri-procedural approach, and implemented risk-stratiﬁed clinical pathways to facili-
tate discharge and reduce length of stay.
Methods: Standardized screening was implemented to conduct multimodality as-
sessments. Following multidisciplinary eligibility decision for TF TAVR by the Heart
Team, additional risk stratiﬁcation was discussed to determine individuals’ appro-
priateness for the peri-procedural “General Anaesthesia and Transesophageal Echo-
cardiography” (“GA/TEE”) and “Awake” (e.g., local anaesthesia) protocols, and the
planning requirements for standard (post-procedure day 3) and early (post-procedure
day 1-2) discharge protocols. Risk-stratiﬁed clinical pathways were developed to
support the patient cohorts.
Results: 144 consecutive patients were accepted for TF TAVR and assigned to risk-
stratiﬁed protocols. The mean age was 827 years, with the proportion of women
ranging from 37% to 42%, and mean STS risk scores between 6.3 and 7.1 in the 4
cohorts. The overall in-hospital outcomes included 2.1% mortality, 0% myocardial
infarction, 0.7% stroke, 2.1% life threatening bleeding, 0.7% new dialysis, and 4.2%
conduction disturbances requiring a new permanent pacemaker. The median length of
stay for all patients was 3 days (IQR 2-3), 2 days (IQR 1-3) in the Awake cohort and 2JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Va(IQR 1-2) in the Early Discharge cohort; 95.8% of patients were discharged home.
The 30-day all-cause hospital readmission rate was 11.1%, ranging from 7% and 8%
in the Awake and Early Discharge cohorts respectively, to 13% in the GA/TEE and
Regular Discharge cohorts; no new deaths occurred between discharge and 30 days.
Conclusions: Early experience with TAVR risk stratiﬁcation, individualized proce-
dure planning and tailored clinical pathways supported by multimodality screening
and multidisciplinary case selection and care results in excellent outcomes and opti-
mized length of stay.
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Background: Chronic kidney injury (CKD) seems to affect survival after TAVI, but
inconsistency in data exists. On the contrary, acute kidney injury (AKI) after TAVI is
prevalent and more clearly associated with mortality. However, an improvement in
serum creatinine is also prevalent after TAVI, possibly due to an improved renal blood
ﬂow. We analyzed the effects of an improved serum creatinine on prognosis in pa-
tients with and without CKD undergoing TAVI.
Methods: All patients undergoing TAVI in our centre for whom multiple serum
creatinine measurements after TAVI were available were prospectively enrolled from
June 2007 to December 2013. CKD was deﬁned as a glomerular ﬁltration rate <
60ml/min. Serum creatinine was measured before and after TAVI. The ratio of the
highest creatinine value after TAVI to before TAVI (CRR) was calculated. A CRR <
1.0 was deﬁned as an improvement, and a CRR 1.5 as AKI, further divided ac-
cording to the AKIN classiﬁcation.
Results: In total, TAVI was performed on 196 (mean age 82.16.4, male 42%, lo-
gistic EuroSCORE 26.916.6%) and 218 (mean age 79.97.5, male 45%, logistic
EuroSCORE 23.815.1%) patients with and without CKD, respectively. In the CKD
group, CRR was < 1.0, 1.0-1.5, and 1.5 in 98 (50.0%), 70 (35.7%) and 28 (14.3%)
of patients, respectively. In the group with normal renal function, CRR was < 1.0, 1.0-
1.5, and 1.5 in 85 (38.9%), 108 (49.5%) and 25 (11.5%) of patients, respectively.
AKI was an independent predictor for early and late mortality. An improvement of
renal function was a negative independent predictor for 2-year mortality in patients
with CKD (HR 0.28, 95% CI 0.15 to 0.51, p< 0.001) but not for patients without
CKD (HR 0.70, 95% CI 0.41 to 1.20, p¼0.19).
Conclusions: The occurrence of AKI is an independent predictor for mortality after
TAVI in patients with and without CKD. However, an improved renal function after
TAVI predicts long-term survival only for patients with prior CKD.
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Background: The aim of this study was to compare the outcomes of transcatheter
aortic valve implantation (TAVI) with the Medtronic CoreValve Revalvivng System
(MCV) with or without preparatory balloon aortic valvuloplasty (PBAV).
Methods: From November 2007 to September 2013 all patients treated with MCV
were included in this analysis. Patients were divided in 2 groups: those where PBAV
was performed and those where MCV was directly implanted. PBAV was performed
according to operator descretion, after consideration of patient anatomical character-
istics. Outcomes were assessed according to valvular academic research consortium
(VARC-2) criteria at 30 days and 1 year.
Results: Of 538 patients that underwent TAVI in our center, 206 were treated with a
MCV via one of the available access routes. Of those, 133 underwent PBAV, while 73
direct valve implantation. Baseline characteristics between the 2 groups were similar.
At 30 days there were no signiﬁcant differences in all-cause and cardiovascular
mortality (3% vs. 5.5%, p ¼ 0.380; and 1.5% vs. 5.5%, p ¼ 0.105; respectively). A
trend for a higher incidence of cardiac tamponade (2.4% vs. 7.8%; p ¼ 0.078) and a
signiﬁcantly higher rate of at least moderate peri-prosthesic aortic regurgitation
(PPAR) requiring valvular balloon post-dilation (VBPD; 35.6% vs. 49.3%, p¼ 0.056)
was noted amongst patients where PBAV was not performed. Conversely patients
who underwent PBAV had more AKI (32.3% vs. 19.4%; p ¼ 0.049). No signiﬁcantlvular disease - Aortic: TAVR B217
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Pull force
towards
LV {N]
Pull force
towards
aorta [N]
Donor 1 33-36 F26 8.6 27
Donor 2 27-29 F29 461* 37.82*
Donor 3 21.5 V23 28 13
Donor 4 25-27 V23 12 3.8
Donor 5 21-23 V26 272* 272*
1* Suture broke due to excessive pull force
2* Stopped pulling at this force without any observed dislodgement.
Key: F – Frame,V- Valve N-Newtons
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comdifferences were observed in PPAR, post-procedural mean gradient, cerebrovascular
events, and 30-day or 1-year VARC-2 composite endpoints between the 2 groups.
Finally, at a median follow-up period of 429 days (IQR 208 - 730), Kaplan-Meier
curves reported no signiﬁcant differences in long-term all-cause (17.8% vs. 23%; Log
Rank p ¼ 0.210) and cardiovascular mortality (13.3% vs. 17.6%; Log Rank p ¼
0.256).
Conclusions: According to our results, direct MCV implantation is safe and effective,
with outcomes comparable to MCV implantation with PBAV. However it was
associated with a higher need of VBPD.
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Background: Transcatheter aortic valve implantation (TAVI) is an emerging treat-
ment option for inoperable or high risk patients. Low implantation (over 8mm) has
been frequently implicated with moderate or severe paravalvular aortic regurgitation
(PVR). However, it has not been evaluated the effect of high implantation on the
outcome of the procedure. The purpose of this study is to assess whether high im-
plantation affects the short- and long-term outcome of the procedure.
Methods: Consecutive patients who underwent TAVI were evaluated. Echocardio-
graphic parameters were recorded before the procedure, at discharge of the patient and
during one month- and one year- follow-up. Permanent pacemaker implantation (PPI),
one month- as well as one year- mortality were recorded according to VARC criteria.
ID was deﬁned as the distance both from the native coronary cusp (NCC) and the left
coronary cusp(LCC) to the deepest edge of the deployed bioprosthesis in the left
ventricle using an ofﬂine program. The patients were separated into two groups ac-
cording to the ID. Group I included all patients with normal (4-8 mm) or low im-
plantation (>8mm) and Group II included those with high (0-4 mm) or over the
annulus implantation(distance from either LCC or NCC < 0 mm).
Results: One hundrend eighty six consecutive patients (815.5 years, 103 males)
who underwent TAVI were recorded.In Group I, peak gradientat discharge (178 vs.
144 mmHg, p< 0.01) and mean gradient at discharge (94 vs. 7,53,5 ,p¼0.02)
was signiﬁcantly higher comparing to Group II, while there was no difference among
two groups during one month- and one year- follow up. Furthermore, the percentage
of patients with need for PPI after TAVI, was signiﬁcantly greater in Group I
comparing to Group II (45.6% vs. 2.9% , p¼0.03). Similarly, one year- all cause
mortality was higher in Group I (13,7% vs. 0%, p¼0.03) while one year- cardio-
vascular as well as one month- and in-hospital mortality did not differ among two
groups.
Conclusions: In conclusion, high implantation seems to have a positive effect on
short- and long-term outcome of the procedure.
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Background: Bicuspid aortic valve (BAV) is the most common congenital heart
disease and may lead to aortic valve stenosis. Although Transcatheter Aortic Valve
Replacement(TAVR) emerged as an alternative therapy in high-risk patients with
tricuspid aortic valve stenosis, presence of a stenotic BAV is often considered a
contraindication, due to its unique anatomy and increased risk of periprocedural
complications. We aimed to assess the feasibility and outcomes of TAVR in high-risk
patients with bicuspid aortic valve stenosis.
Methods: The study is a prospective, single-centre registry of patients with BAV
stenosis treated with TAVR. Periprocedural safety, hemodynamic and clinical
outcome was observed during patient follow-up.
Results: Of 130 high-risk patients with severe aortic stenosis who underwent
TAVR from January 2009 to May 2014 in our centre, 15 (12.5%) patients had
documented BAV. Patients were aged 769 years (range 56-90), with mean Lo-
gistic EuroScore I of 2011%, all in New York Heart Association functional class
III. The mean aortic valve area was 0.760.36 cm2, mean gradient was 45.315.1
mmHg and mean LVEF was 50.512.4%. The procedure was performed using
transfemoral access in 13 (87%), transaortic in 1 (6.5%) and transapical in 1
(6.5%) patient. Medtronic CoreValve prosthesis was implanted in 9 (60%) and
Edwards Sapien XT in 6 (40%) patients. TAVI procedure was successful in 13
patients (87%). Major adverse events according to the second Valvular AcademicB218 JACC Vol 64/11/Suppl B j SepResearch Consortium deﬁnitions were present in 2 patients: 1 periprocedural death
(Edwards Sapien XT 29) and 1 periprocedural stroke (Medtronic CoreValve 26).
Importantly, both complications were related to prosthesis dislocation from the
bicuspid aortic valve annulus. Postprocedural aortic valve mean gradient was 82
mmHg and AVA 1.40.4 cm2. After a mean follow-up of 1312 months (range
1-39) no further adverse events occurred. All survivors remained in NYHA class I
or II.
Conclusions: Our initial experience suggests TAVI using CoreValve and Sapien XT
prostheses in high risk patients with stenotic bicuspid aortic valve is feasible, leading
to good short term hemodynamic and clinical improvement.
TCT-746
Mechanism of Transcatheter Aortic Valve Replacement Anchoring
Dmitry Levin1, Tamir Levi2, mark reisman3
1Seattle Science Foundation, Seattle, WA, 2Edwards Life Sciences Corporation,
Tel Aviv, Israel, 3university of washington, Seattle, WA
Background: TAVR success requires both anchoring and sealing in the native aortic
valve complex. These two processes may be unique and not interdependent. Using
undersized TAVR device we tested the mechanism of TAVR anchoring
Methods: Five cadaveric hearts with severe aortic stenosis were imaged with
CT-scanning. An annular diameter was measured, and a calcium score was assigned.
The hearts were pressurized such that SAPIEN 3 (Edwards Lifesciences) valves and
frames (implants) could be delivered and deployed. Two endoscopes were positioned,
one at the apex and the other in the ascending aorta, to enable visibility. Depending on
annulus size, an S3 valve or frame was chosen to be implanted under ﬂuoroscopic and
endoscopic guidance such that the implant would be smaller than the annulus
currently recommended per Edwards instructions for use (IFU), Strings were attached
at three points both at the inﬂow and outﬂow portions of the Edwards implants to pull
and measure the force required to move the prosthesis. The implants were deployed at
discrete inﬂation volume until the frame initially engaged with the native leaﬂets.
Dimensions were measured, and pull forces were applied in both the LV and aortic
directions until the implant demonstrated movement . A gauge attached to the strings,
measured dislodgement forces.
Results: See table
Conclusions: High pull forces are required to displace undersized TAVR valves in the
absence of annular interaction with the prosthesis indicating that: anchoring is at the
native leaﬂet level and that anchoring and sealing may be two distinct processes.TCT-747
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Background: Transcatheter aortic valve intervention (TAVI) is a recognized life-
saving treatment for those who are at high risk for conventional aortic valve surgery.
The ﬁnancial cost of a TAVI “pathway” from the time of referral to the time of
hospital discharge was assessed.
Methods: Consecutive patients (n¼46) who underwent TAVI between February
2012 and December 2013 at Hammersmith Hospital, London, UK were
included in this retrospective study. The analysis included costs of outpatient
appointment, investigations prior to the procedure, the TAVI procedure as well as
post-procedural costs including the cost of pacemaker implantation. NHS
tariff costs were used for the assessment. Comparison of the costs incurred
following implantation of the Edwards and CoreValve bioprostheses was also
performed.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
